FAQ Directory

Here are some of the most frequently asked questions about NCQA’s various programs. If you don’t see what you are looking for in one of the entries below, you can  ask a question through My NCQA.

Filter Results
  • Save
    Save your favorite pages and receive notifications whenever they’re updated. You will be prompted to log in to your NCQA account.
  • Email
    Share this page with a friend or colleague by Email. We do not share your information with third parties.
  • Print this page.

5.15.2012 Collecting feedback from program participants Is an organization required to collect feedback from all programs and all program participants, or may the organization choose from whom to collect feedback?

Organizations must include all programs or population segments to assess for WHP 9, Element A.

Data collection must be across all programs and include eligible participants. If an organization uses a sample, the sample must be randomized to give all eligible participants an equal chance of being included.

This applies to the following Programs and Years:

5.15.2012 Verification of certification for an unrecognized board Does NCQA only accept ABMS and AOA sponsored boards as verification sources? What does NCQA require for verification of boards from non-ABMS or non-AOA boards if the practitioner claims to be board certified?

No. With the exception of ABMS or AOA sponsored boards, NCQA requires organizations to determine and list specialty boards they accept within their credentialing policies and procedures. At a minimum, at least annually, organizations must obtain written confirmation from the specialty board that it performs primary-source verification of education and training. A specialty board that provides annual written confirmation that it conducts primary source verification of education and training can be used as an acceptable source for verification of education and training if the organization names the specialty board in its policies and procedures.

This applies to the following Programs and Years:

4.16.2012 Proportion of Days Covered by Medications (PDC) The Eligible Population criteria state that continuous enrollment for PDC is the index prescription date (IPD) through the end of the measurement year or until death or disenrollment, and that there is no allowable gap. Are members with two separate enrollment periods that meet the 90 day requirement excluded because of the gap in enrollment, or are they counted as two separate measurement periods?

Because there are no allowable gaps in this measure, exclude members who were not continuously enrolled, including members who had more than one 90+ day measurement period.

This applies to the following Programs and Years:

4.16.2012 Meaningful Use of Health Information Technology (MUHIT) In the November 2011 release of the MY2011 P4P Manual, the examples for scoring of the MUHIT domain in the Description and Domain Structure sections (pp 114 and 115) seem to have incorrect calculations. Is this an error?

Yes. The example on page 114 should read as follows:

100 out of 100 PCPs meet the criteria = 100%

_ 5 points for certified and 3.75 for non-certified

25 of 100 certified = ((25% * 5) = 1.25)

75 of 100 non-certified = ((75% * 3.75) = 2.81)

Total points = ((1.25+ 2.81) = 4.06)

The example on page 115, in the Point allocation for POs using ONC-ATCB certified software section, should read as follows:

For example, if a PO earned 60 points, its overall calculated P4P score would be 18. Scores are rounded to the nearest whole number.

These errors will be corrected in the September 2012 release of the MY 2012 manual.

This applies to the following Programs and Years:

4.16.2012 Use of Imaging Studies for Low Back Pain (LBP) In the November 2011 release of the MY2011 P4P Manual, the table LBP-D contains an invalid CPT code, 72011. Is this an error?

Yes. The first CPT code in the table should be 72010. This error will be corrected in the September 2012 release of the MY 2012 manual.

This applies to the following Programs and Years:

3.16.2012 Asthma Medication Ratio (AMR) In the November 2011 release of the MY 2011 P4P specifications, Table AMR-C: Asthma Medications does not match exactly with Table ASM-C in the 2012 HEDIS volume. Is this an error?

There is an error in the manual. In the Table AMR-C: Asthma Medications, in the row Inhaled steroid combinations the drug Bluticasone-salmeterol should read Fluticasone-salmeterol.

This error will be corrected in the September 2012 release of the MY 2012 manual.

This applies to the following Programs and Years:

3.16.2012 Proportion of Days Covered by Medications (PDC) In the November 2011 release of the MY2011 P4P specifications, the wording under Definitions and Eligible Population is confusing. The definition of the Index Prescription Date (IPD) states that the index date should occur at least 91 days before the end of the measurement period, but under Continuous Enrollment, the manual states that the IPD must occur at least 91 days prior to the end of the measurement year. Should we be looking back from the end of the measurement period or the end of the measurement year?

The Index Prescription Date (IPD) should occur at least 91 days before the end of the measurement period, as stated in the definition of IPD. The Continuous Enrollment section should refer to the measurement period, for both self-reporting POs and for health plans.

This error will be corrected in the September 2012 release of the MY 2012 manual.

This applies to the following Programs and Years:

3.16.2012 Diabetes Care Blood Pressure Control (<140/90 mm Hg) In the November 2011 release of the MY 2011 P4P specifications, Blood Pressure Control (<140/90 mm Hg) for Diabetes replaced exclusions with the note, The blood pressure reading must be in conjunction with an outpatient visit code or a nonacute inpatient visit code from Table CDC-C. This new note requires physician organizations to map blood pressure pulled from a registry to claim data to identify the specific visit codes. This change is extremely burdensome! Why was it necessary?

P4P made this change to align with HEDIS, but did not consider the unintended impact it will have on POs, which must pull the information from EHRs. Because of the burden to POs, P4P will revert to the prior language for this measure, outlined below.

When identifying the most recent BP reading noted during the measurement year, do not include BP readings that meet the following criteria.

BPs taken during an acute inpatient stay (Table CDC-O)

BPs taken during an ED visit (Table CDC-P)

BPs taken during an outpatient visit where a diagnostic test or surgical procedure was performed (e.g., sigmoidoscopy, removal of a mole) or BPs obtained the same day as a major diagnostic or surgical procedure (e.g., stress test, administration of IV contrast for a radiology procedure, endoscopy) (Table CDC-Q)

BP readings taken by the member.

This applies to the following Programs and Years:

3.16.2012 Encounter Rate Threshold for Clinical Measures Table ENR-F Option A states to use the CMS ASC Approved HCPCS Codes and Payment Rates file and to only use the spreadsheet titled, "Addendum AA_ASC Covered Surgical Procedures (ASC_AddAA.csv) for October 2011". This exact file name is not found in the zip file on the CMS website. Please confirm the file and tab that should be used.

The file name has been updated on the CMS website. To reflect this change, the note under Table ENR-F should read as follow: * These codes can be found on the CMS Web site (http://www.cms.hhs.gov/ASCPayment/11_Addenda_Updates.asp#TopOfPage/). Click October 2011 ASC Approved HCPCS codes and Payment Rates. Use only the spreadsheet titled, Oct11_ASC_Add_AA-BB-DD1_ExtAct.xlsx, and the tab titled Oct11_ASC_AddAA-ExtAct. Only use 5-digit all-numeric CPT codes (Level 1 HCPCS) in the spreadsheet; do not include any codes with an alpha value. This update will be reflected in the September 2012 release of the MY 2012 manual.

This applies to the following Programs and Years:

3.16.2012 Appropriate Testing for Children With Pharyngitis (CWP) In the November 2011 release of the MY 2011 P4P specifications, Table CWP-C: Antibiotic Medications does not match exactly with Table CWP-C in the 2012 HEDIS volume. Is this an error?

There is an error in the manual. In Table CWP-C: Antibiotic Medications,

in the row First generation cephalosporins, the drug Cephradine should not be in the table,

in the row Macrolides the drug Erythromycin estolate should not be in the table,

in the row Third generation cephalosporins, the drug Cefditoren should be included in the table.

These errors will be corrected in the September 2012 release of the MY 2012 manual.

This applies to the following Programs and Years:

3.16.2012 Continuous Enrollment and Allowable Gaps Over Multiple Years In the MY2011 P4P Manual, are the dates correct in the example for Continuous Enrollment and Allowable Gaps Over Multiple Years? They do not seem to match up to the description of gaps in enrollment.

There is an error in the manual. The first date in the example should be November 30, 2010. The full example should read as follows:

For example, in the MY 2011 Breast Cancer Screening measure (which requires 2 years of continuous enrollment), a member who disenrolls on November 30, 2010 (the year prior to the measurement year), and re-enrolls on February 1, 2011 (the measurement year), is considered continuously enrolled as long as there were no other gaps in enrollment during either year. The member has one gap of 31 days (December 1_31) in 2010 and one gap of 31 days (January 1_31) in 2011.

This error will be corrected in the September 2012 release of the MY 2012 manual.

This applies to the following Programs and Years:

3.16.2012 Chlamydia Screening in Women (CHL) In the November 2011 release of the MY 2011 P4P specifications, Table CHL-A: Prescriptions to Identify Contraceptives does not match exactly with Table CHL-A in the 2012 HEDIS volume. Is this an error?

There is an error in the manual. In Table CHL-A: Prescriptions to Identify Contraceptives,

in the row Contraceptives, the drugs Estradiol-medroxyprogesterone, Levonorgestrel, Medroxyprogesterone, and Norethindrone should be included in the table,

the drug Levonorgestrel-medroxyprogesterone should not be in the table.

These errors will be corrected in the September 2012 release of the MY 2012 manual.

This applies to the following Programs and Years: